Skip to main content
    A

    Avalo Therapeutics Inc (AVTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.37
    -0.39 (-5.03%)

    Market Cap: $448.71M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Avalo Therapeutics Inc (AVTX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Avalo Therapeutics reported revenue of $59.00K for the fiscal year ended Dec 31, 2025, down 86.6% from the year before. That year, net income was -$78.26M with a net margin of -132642.4%, operating cash flow was -$51.46M and free cash flow was -$51.46M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$18.95M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue fell from $1.15M, a compound annual decline of 28.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$59.00K-86.6%100.0%-123601.7%-132642.4%
    Dec 2024$441.00K-77.1%183.0%-15535.6%-7965.8%
    Dec 2023$1.92M-89.3%33.3%-1421.6%-1639.5%
    Dec 2022$18.05M+234.4%81.0%-207.4%-230.8%
    Dec 2021$5.40M-19.4%72.4%-1521.6%-1563.1%
    Dec 2020$6.70M-0.8%95.5%-1087.4%-947.9%
    Dec 2019$6.75M-67.3%108.4%-239.1%-238.1%
    Dec 2018$20.63M-25.8%84.2%-171.5%-194.2%
    Dec 2017$27.81M+2312.3%97.7%49.9%42.7%
    Dec 2016$1.15MN/A100.0%-1394.6%-1428.6%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$59.00K$441.00K$1.92M$18.05M$5.40M$6.70M$6.75M$20.63M$27.81M$1.15M
    Cost of revenue$0-$366.00K$1.28M$3.43M$1.49M$300.00K-$566.52K$3.26M$635.65K$0
    Gross profit$59.00K$807.00K$640.00K$14.62M$3.91M$6.40M$7.32M$17.37M$27.18M$1.15M
    Research and development$50.08M$52.08M$13.78M$31.31M$59.84M$57.74M$11.76M$24.51M$4.37M$10.15M
    Operating income-$72.92M-$68.51M-$27.35M-$37.44M-$82.13M-$72.84M-$16.14M-$35.38M$13.89M-$16.08M
    Net income-$78.26M-$35.13M-$31.54M-$41.66M-$84.38M-$63.50M-$16.07M-$40.05M$11.87M-$16.47M
    EBITDAN/A-$38.16M-$26.13M-$35.91M-$79.70M-$65.38M-$12.12M-$30.48M$14.42M-$15.98M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$59.00K$0$0$0$192.00K$249.00K$0$0$570.00K
    Gross profit$0$0$0$59.00K$0$0$0$107.00K$963.00K-$343.00K$80.00K$792.00K
    Operating income-$23.40M-$31.52M-$20.90M-$19.74M-$19.20M-$19.32M-$14.67M-$13.31M-$12.86M-$9.57M-$32.77M-$7.66M
    Net income-$18.95M-$36.36M-$19.63M-$13.72M-$30.63M-$20.77M-$13.15M-$35.34M$23.04M$98.46M-$121.29M-$8.17M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $392.00K by $15.47M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$116.46M$150.73M$20.99M$33.37M$80.21M$43.76M$36.11M$70.25M$42.81M$5.77M
    Current assets$105.29M$138.89M$8.39M$16.42M$61.84M$26.00M$17.72M$21.93M$10.67M$5.66M
    Cash and equivalents$15.86M$134.55M$7.42M$13.17M$54.59M$18.92M$3.61M$10.65M$2.47M$5.13M
    Total liabilities$33.41M$17.70M$13.69M$44.28M$57.13M$19.19M$15.11M$49.34M$14.95M$5.56M
    Short-term debt$392.00K$568.00K$537.00K$5.93M$0$426.00K$155.81K$859.67K$0$2.35M
    Long-term debtN/AN/AN/A$13.49M$32.83MN/AN/A$14.33M$0N/A
    Shareholder equity$83.05M$133.03M$7.30M-$10.91M$23.08M$24.56M$21.00M$20.91M$27.86M$207.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$481.43M$490.78M$99.89M$116.46M$125.10M$126.58M$138.52M$150.73M$98.45M$108.31M$123.73M$20.99M
    Total liabilities$44.88M$42.12M$31.57M$33.41M$33.55M$22.01M$15.91M$17.70M$75.72M$110.46M$224.81M$13.69M
    Cash and equivalents$64.99M$85.38M$24.99M$15.86M$26.96M$42.29M$125.05M$134.55M$81.86M$93.43M$110.18M$7.42M
    Shareholder equity$436.55M$448.66M$68.32M$83.05M$91.55M$104.57M$122.61M$133.03M$21.08M-$13.61M-$112.54M$7.30M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$51.46M-$49.06M-$30.68M-$26.75M-$70.89M-$40.54M-$19.13M-$3.13M$12.58M-$14.57M
    Capital expenditures$0$0$158.00K$95.00K$113.00K$63.00K$262.01K$564.41K$23.32K$34.88K
    Free cash flow-$51.46M-$49.06M-$30.84M-$26.85M-$71.00M-$40.60M-$19.40M-$3.69M$12.56M-$14.61M
    Dividends paidN/AN/AN/A$14.81M$32.90MN/A$1.08MN/AN/AN/A
    Share repurchases$462.00K$1.73M$0N/AN/AN/AN/AN/AN/AN/A
    Investing cash flow-$81.72M$356.00K-$133.00K-$95.00K-$113.00K$11.13M-$443.00K$865.46K-$18.91M-$34.88K
    Financing cash flow$14.59M$175.85M$25.04M-$14.70M$106.76M$44.78M$12.56M$10.40M$3.74M-$1.43M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$11.54M-$19.99M-$17.69M-$14.25M-$16.36M-$11.39M-$9.46M-$15.04M-$11.53M-$16.28M-$6.20M-$2.77M
    Capital expendituresN/AN/A$0$0$0$0$0$0$0$0$0$158.00K
    Free cash flowN/AN/A-$17.69M-$14.25M-$16.36M-$11.39M-$9.46M-$15.04M-$11.53M-$16.28M-$6.20M-$2.92M
    Last 12 quarters

    Frequently Asked Questions About AVTX

    What is Avalo Therapeutics' annual revenue?

    Avalo Therapeutics reported revenue of $59.00K for the fiscal year ended Dec 31, 2025.

    How fast is Avalo Therapeutics' revenue growing?

    Revenue was down 86.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -85.2%.

    Is Avalo Therapeutics profitable?

    No. Avalo Therapeutics reported net income of -$78.26M for the fiscal year ended Dec 31, 2025, with a net margin of -132642.4%.

    How much free cash flow does AVTX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$51.46M minus capital expenditures of $0 produced free cash flow of -$51.46M.

    How much debt does Avalo Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $392.00K and cash and equivalents of $15.86M.